Little House Capital LLC Sells 2,466 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Little House Capital LLC reduced its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 53.7% in the first quarter, HoldingsChannel reports. The institutional investor owned 2,124 shares of the medical research company’s stock after selling 2,466 shares during the period. Little House Capital LLC’s holdings in Thermo Fisher Scientific were worth $1,235,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the stock. Northwest Financial Advisors bought a new position in Thermo Fisher Scientific during the fourth quarter valued at $29,000. True Wealth Design LLC lifted its position in shares of Thermo Fisher Scientific by 1,275.0% during the fourth quarter. True Wealth Design LLC now owns 55 shares of the medical research company’s stock valued at $29,000 after buying an additional 51 shares during the last quarter. Pineridge Advisors LLC purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter valued at about $39,000. Cape Investment Advisory Inc. increased its holdings in shares of Thermo Fisher Scientific by 52.0% during the fourth quarter. Cape Investment Advisory Inc. now owns 76 shares of the medical research company’s stock valued at $40,000 after acquiring an additional 26 shares in the last quarter. Finally, Raleigh Capital Management Inc. increased its holdings in Thermo Fisher Scientific by 49.1% in the 3rd quarter. Raleigh Capital Management Inc. now owns 82 shares of the medical research company’s stock worth $41,000 after buying an additional 27 shares during the period. 89.23% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

TMO has been the topic of a number of recent analyst reports. Evercore ISI increased their target price on Thermo Fisher Scientific from $575.00 to $610.00 and gave the company an “outperform” rating in a research report on Thursday, April 4th. Citigroup initiated coverage on Thermo Fisher Scientific in a research report on Monday, March 18th. They set a “neutral” rating and a $620.00 price objective for the company. Deutsche Bank Aktiengesellschaft lifted their target price on Thermo Fisher Scientific from $600.00 to $610.00 and gave the company a “buy” rating in a research report on Thursday, April 25th. Jefferies Financial Group reiterated a “buy” rating and issued a $650.00 price objective (up previously from $600.00) on shares of Thermo Fisher Scientific in a research note on Monday, June 3rd. Finally, HSBC boosted their target price on Thermo Fisher Scientific from $660.00 to $670.00 and gave the stock a “buy” rating in a research note on Tuesday, April 30th. Five research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $607.06.

Thermo Fisher Scientific Stock Down 2.1 %

Shares of TMO traded down $11.59 during trading hours on Monday, hitting $541.41. 884,066 shares of the company were exchanged, compared to its average volume of 1,546,453. The company has a market cap of $206.67 billion, a PE ratio of 35.47, a PEG ratio of 2.58 and a beta of 0.77. The firm’s 50 day moving average is $574.84 and its 200-day moving average is $563.36. Thermo Fisher Scientific Inc. has a 52 week low of $415.60 and a 52 week high of $603.82. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.33 and a current ratio of 1.70.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, topping the consensus estimate of $4.70 by $0.41. The company had revenue of $10.35 billion for the quarter, compared to analyst estimates of $10.14 billion. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. On average, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 21.65 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, July 15th. Stockholders of record on Friday, June 14th will be given a dividend of $0.39 per share. The ex-dividend date is Friday, June 14th. This represents a $1.56 annualized dividend and a dividend yield of 0.29%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.01%.

Insider Transactions at Thermo Fisher Scientific

In related news, SVP Michael A. Boxer sold 2,000 shares of the company’s stock in a transaction dated Friday, April 26th. The stock was sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the sale, the senior vice president now owns 13,083 shares in the company, valued at $7,430,359.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, SVP Michael A. Boxer sold 2,000 shares of the stock in a transaction that occurred on Friday, April 26th. The stock was sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the sale, the senior vice president now owns 13,083 shares of the company’s stock, valued at $7,430,359.02. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $567.28, for a total value of $5,672,800.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at approximately $70,238,340.48. The disclosure for this sale can be found here. Insiders sold 22,000 shares of company stock valued at $12,532,780 over the last three months. Company insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.